Publish in this journal
Journal Information
Share
Share
Download PDF
More article options
ePub
Visits
...
Review Article
DOI: 10.1016/j.reumae.2020.02.007
Available online 24 November 2020
Pneumocystis jirovecii in immunocompromised patients with rheumatic diseases
Pneumocystis jirovecii en pacientes inmunocomprometidos con enfermedades reumáticas
Visits
...
Paloma Vela Casasemperea,b,
Corresponding author
palomavela62@gmail.com

Corresponding author.
, Paloma Ruiz Torregrosac, Raquel García Sevilac
a Sección de Reumatología, Hospital General Universitario de Alicante, ISABIAL, Alicante, Spain
b Universidad Miguel Hernández, Alicante, Spain
c Servicio de Neumología, Hospital General Universitario de Alicante, Alicante, Spain
Received 07 December 2019. Accepted 28 February 2020
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Tables (3)
Table 1. NPJ prophylaxis regimes.
Table 2. Side effects of TMP-SMX.
Table 3. Risk factors for the development of NPJ in patients with RD&SA. Modified from Wolf et al.21.
Show moreShow less
Abstract

Infections, including opportunistic infections, are a major and frequent cause of morbidity and mortality in patients with systemic autoimmune and rheumatic diseases. Pneumocystis jirovecii pneumonia, classically considered to be typical of HIV patients, transplanted patients or patients treated with oncological chemotherapy, is appearing increasingly frequently in these patients. Therefore, rheumatologists should know its mechanism of production, clinical manifestations, treatment and prophylaxis, all of which are addressed in this review.

Keywords:
Pneumocystis jirovecii
Immunosuppression
Rheumatic disease
Autoimmune disease
Prophylaxis
Resumen

Las infecciones, entre ellas las oportunistas, constituyen una causa importante y frecuente de morbilidad y mortalidad en los pacientes con enfermedades reumáticas y autoinmunes sistémicas. La neumonía por Pneumocystis jirovecii, clásicamente considerada propia de pacientes VIH, trasplantados o tratados con quimioterapia oncológica, aparece cada vez con mayor frecuencia en estos pacientes. Es por ello conveniente que los reumatólogos conozcan su mecanismo de producción, manifestaciones clínicas, tratamiento y profilaxis, aspectos todos ellos abordados en esta revisión.

Palabras clave:
Pneumocystis jirovecii
Inmunosupresión
Enfermedad reumática
Enfermedad autoinmune
Profilaxis

Article

These are the options to access the full texts of the publication Reumatología Clínica (English Edition)
Member
If you are member of Sociedad Española de Reumatología (SER) or the Colegio Mexicano de Reumatología (CMR):
Please go to the member area of SER or CMR and log in.
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Reumatología Clínica (English Edition)

Comprar
Comprar acceso al artículo

Comprando el artículo el PDF del mismo podrá ser descargado

Precio 19,34 €

Comprar ahora
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
Email
Idiomas
Reumatología Clínica (English Edition)

Subscribe to our newsletter

Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.